Matrixyl® 3000
(A synergistic complex of Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7)
This advanced matrikine peptide complex mimics naturally occurring collagen fragments that signal skin damage. At the cellular level, Matrixyl® 3000 activates dermal fibroblasts by binding to cell receptors involved in wound-repair signaling, stimulating the synthesis of Collagen I, III, and IV, fibronectin, and hyaluronic acid, which are key components of the extracellular matrix (ECM) (Pintea et al., 2025). Simultaneously, Palmitoyl Tetrapeptide-7 downregulates pro-inflammatory cytokines such as IL-6, reducing chronic low-grade inflammation that accelerates collagen degradation. This dual mechanism both rebuilds lost dermal structure and protects existing collagen from breakdown (Veiga et al., 2023).
Result: Smoother skin texture, improved firmness, and visibly reduced fine lines through collagen renewal and inflammation control.
Matrixyl® Synthe’6®
(Palmitoyl Tripeptide-38)
Matrixyl® Synthe’6® is a next-generation remodeling peptide designed to restore skin architecture from within. At the cellular level, it stimulates fibroblast gene expression responsible for the synthesis of six major dermal matrix components: Collagen I, III, and IV, fibronectin, laminin-5, and hyaluronic acid. This targeted activation leads to increased dermal density and improved organization of the extracellular matrix, particularly within wrinkle folds. By enhancing matrix deposition and dermal thickness, Matrixyl® Synthe’6® counteracts skin thinning and loss of elasticity associated with aging.
Result: Plumper, denser skin with visibly filled wrinkles and long-term structural rejuvenation.